Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
Completed
Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia
Phase 4
2006-09-01
To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous
infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in
Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate
of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and
rates of relapse after 28 days.
Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or
microbiological cure greater than the intermittent administration.
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
Completed
Clinica Palermo, Bogota
Phase 4
2006-09-01
To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous
infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in
Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate
of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and
rates of relapse after 28 days.
Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or
microbiological cure greater than the intermittent administration.
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
Completed
Fundación San Carlos, Bogota
Phase 4
2006-09-01
To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous
infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in
Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate
of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and
rates of relapse after 28 days.
Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or
microbiological cure greater than the intermittent administration.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
